Molecular Diagnostics Market

The molecular diagnostics market is valued at an estimated USD 21.68 billion in 2026 and is projected to reach USD 32.56 billion by 2031, reflecting a CAGR of 8.5%. The market is experiencing significant growth, driven by technological advancements and rising healthcare needs. The increasing prevalence of infectious diseases, cancer, and genetic disorders is fueling demand for accurate, early diagnostic solutions. Technological innovations in PCR, next-generation sequencing (NGS), and isothermal amplification have enhanced test speed, sensitivity, and versatility, supporting broader clinical adoption. Additionally, expanding access to healthcare in emerging markets, increased investment in research and development, and rising awareness of preventive health further contribute to market expansion.

In May 2026, Illumina, Inc. received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive as a Class III/IV Medical Device (Specially Controlled Medical Device) in Japan. Likewise, in December 2025, F. Hoffmann-La Roche Ltd. (Switzerland) received CE certification for its new cobas 6800/8800 systems 2.0. This updated version delivers major efficiency gains for laboratories by optimizing resource use, minimizing downtime, consolidating test menus, and boosting throughput. These enhancements aim to deliver a more seamless and effective diagnostic experience for healthcare providers and patients.

To know about the assumptions considered for the study download the pdf brochure

The key players in the molecular diagnostics market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), QIAGEN N.V. (Netherlands), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott (US), Siemens Healthineers AG (Germany), Myriad Genetics, Inc. (US), Becton, Dickinson and Company (BD) (US), Agilent Technologies, Inc. (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), Seegene Inc. (South Korea), Sansure Biotech Inc. (China), and Revvity, Inc. (US).

Danaher (US) has become a prominent name in the global molecular diagnostics market, supported by a strong US base and a clear strategy for international expansion. This solid domestic footing serves as a launchpad for entering fast-growing emerging economies, helping the company extend its global presence. Danaher focuses on product innovation to keep pace with the evolving needs of a diverse global customer base, reinforcing its industry leadership. Steady investment in research and development, together with efficient supply chain operations, further strengthens its competitive edge. The company pursues organic growth through new product launches and regulatory approvals, and it also uses strategic partnerships and acquisitions to complement its technology portfolio and broaden its customer base. With a robust innovation pipeline, operational excellence, and a strategic focus on unmet clinical needs, Danaher is well positioned to maintain its leadership in molecular diagnostics.

F. Hoffmann-La Roche Ltd. (Switzerland) commands a significant share of the global molecular diagnostics market, driven by its broad geographic reach and strategic growth initiatives. Its well-developed distribution network spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, keeping products consistently available in key markets and limiting exposure to regional demand swings. Roche strengthens its market leadership through targeted acquisitions that enhance its technology portfolio. These strategic investments help consolidate its position in high-demand segments of the molecular diagnostics market.

Illumina, Inc. (US) holds a strong position in the molecular diagnostics market, largely due to its leadership in next-generation sequencing (NGS) technologies. The company has expanded its global footprint through targeted investments and partnerships in fast-growing emerging markets. This international expansion broadens its revenue base and makes advanced genomic diagnostics more accessible worldwide. Illumina offers a wide range of FDA- and CE-cleared products for clinical applications such as oncology, reproductive health, rare genetic disorders, and infectious disease testing. Its sequencing platforms are widely adopted by laboratories and hospitals for accurate, high-throughput molecular analysis. Backed by a strong innovation pipeline and a global presence, Illumina is well positioned to maintain its leadership in molecular diagnostics.

Market Ranking

The five leading players in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMérieux (France), and Hologic, Inc. (US). Each contributes to market growth through innovation, a broad global presence, and a wide range of products and services. Danaher continues to strengthen its position through steady product development, regulatory approvals, and international expansion. Roche draws on its extensive diagnostics infrastructure and high-throughput molecular platforms to provide reliable solutions in clinical settings. Illumina plays a key role in advancing genomic diagnostics with next-generation sequencing technologies that improve the accuracy and efficiency of molecular testing. bioMérieux focuses on molecular solutions for detecting infectious diseases and syndromic testing, supporting timely clinical decision-making. Hologic remains a major player in women's health diagnostics, offering high-throughput systems and a robust test menu. Together, these companies shape the development of the molecular diagnostics market through technological leadership and global accessibility.

Related Reports:

Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application (Infectious, Cancer), Technique, Clinical Application, End User- Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]